作者
Shiva Bamezai,Alex Jose Pulikkottil,Tribhuwan Yadav,Vegi M. Naidu,Julia Mueller,Jasmin Mark,Tamoghna Mandal,Kristin Feder,Susann Lehle,Chenlin Song,R. Rosler,Sebastian Wiese,Jessica I. Hoell,Andreas Kloetgen,Aly Karsan,Ankita Kumari,Luke Wojenski,Amit Sinha,Irene González-Menéndez,Leticia Quintanilla-Martı́nez,Elisa Donato,Andreas Trumpp,Elisabeth Kruse,Stephan Hamperl,Lee Zou,Vijay P.S. Rawat,Christian Buske
摘要
RNA-binding proteins (RBPs) form a large and diverse class of factors many members of which are overexpressed in hematological malignancies. RBPs participate in various processes of mRNA metabolism and prevent harmful DNA:RNA hybrids or R-loops. Here we report that PIWIL4, a germ stem cell-associated RBP belonging to the RNase H-like superfamily, is overexpressed in acute myeloid leukemia patients and is essential for leukemic stem cell function and AML growth, but dispensable for healthy human hematopoietic stem cells. In AML cells, PIWIL4 binds to a small number of known piwi-interacting RNA. It instead largely interacts with mRNA annotated to protein-coding genic regions and enhancers that are enriched for genes associated with cancer and human myeloid progenitor gene signatures. PIWIL4 depletion in AML cells downregulates human myeloid progenitor signature and LSC-associated genes and upregulates DNA damage signalling. We demonstrate that PIWIL4 is an R-loop resolving enzyme that prevents R-loop accumulation on a subset of AML and LSC-associated genes, and maintains their expression. It also prevents DNA damage, replication stress, and activation of the ATR pathway in AML cells. PIWIL4 depletion potentiates sensitivity to pharmacological inhibition of the ATR pathway and creates a pharmacologically actionable dependency in AML cells.